Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FOSTER CITY, CALIF., JULY 22, 2026 (GLOBE NEWSWIRE) -- GERON CORPORATION (NASDAQ: GERN), A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY REPORTED THAT, EFFECTIVE JULY 17, 2026, IT GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 202,500 SHARES OF COMMON STOCK TO FIVE NEWLY HIRED EMPLOYEES AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH GERON.

GERON CORPORATION REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

FOSTER CITY, CALIF., JULY 22, 2026 (GLOBE NEWSWIRE) -- GERON CORPORATION (NASDAQ: GERN), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY AIMING TO CHANGE LIVES BY CHANGING THE COURSE OF BLOOD CANCER, TODAY ANNOUNCED THAT IT WILL RELEASE ITS SECOND QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS BEFORE THE MARKET OPENS ON WEDNESDAY, AUGUST 5, 2026, VIA PRESS RELEASE, WHICH WILL BE AVAILABLE ON THEINVESTORS AND MEDIA SECTION OF THE COMPANY'S WEBSITE. GERON WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:00 A.M. EASTERN TIME.

GERON PLANS TO ANNOUNCE SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 5, 2026

CAMBRIDGE, MASS., JULY 15, 2026 (GLOBE NEWSWIRE) -- RECTIFY PHARMACEUTICALS, A BIOTECHNOLOGY COMPANY ADVANCING POSITIVE FUNCTIONAL MODULATORS (PFMS), A NOVEL CLASS OF ORAL SMALL MOLECULES DESIGNED TO RESTORE AND ENHANCE MEMBRANE PROTEIN FUNCTION, TODAY ANNOUNCED THE APPOINTMENT OF CONSTANTINE CHINOPOROS AS EXECUTIVE CHAIRMAN OF THE COMPANY'S BOARD OF DIRECTORS, EFFECTIVE IMMEDIATELY.

RECTIFY PHARMACEUTICALS ANNOUNCES APPOINTMENT OF CONSTANTINE CHINOPOROS AS EXECUTIVE CHAIRMAN

FOSTER CITY, CALIF., JULY 14, 2026 (GLOBE NEWSWIRE) -- GERON CORPORATION (NASDAQ: GERN), A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY REPORTED THAT IT GRANTED AN EQUITY AWARD IN THE FORM OF A STOCK OPTION TO PURCHASE 1,700,000 SHARES OF GERON COMMON STOCK TO CHINMAYA RATH, GERON'S NEW CHIEF BUSINESS OFFICER, AS AN INDUCEMENT MATERIAL TO HIS ACCEPTANCE OF EMPLOYMENT WITH GERON.

GERON CORPORATION REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

MR. RATH BRINGS SENIOR LEADERSHIP EXPERIENCE IN BUSINESS DEVELOPMENT ACROSS A RANGE OF BIOPHARMACEUTICAL COMPANIES MR. RATH BRINGS SENIOR LEADERSHIP EXPERIENCE IN BUSINESS DEVELOPMENT ACROSS A RANGE OF BIOPHARMACEUTICAL COMPANIES

GERON ANNOUNCES APPOINTMENT OF CHINMAYA RATH AS CHIEF BUSINESS OFFICER

FOSTER CITY, CALIF., JUNE 18, 2026 (GLOBE NEWSWIRE) -- GERON CORPORATION (NASDAQ: GERN), A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY REPORTED THAT, EFFECTIVE JUNE 17, 2026, IT GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 690,000 SHARES OF COMMON STOCK TO EIGHT NEWLY HIRED EMPLOYEES AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH GERON.

FOSTER CITY, CALIF., JUNE 01, 2026 (GLOBE NEWSWIRE) -- GERON CORPORATION (NASDAQ: GERN), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY AIMING TO CHANGE LIVES BY CHANGING THE COURSE OF BLOOD CANCER, TODAY ANNOUNCED THAT MEMBERS OF THE MANAGEMENT TEAM ARE SCHEDULED TO PARTICIPATE IN A FIRESIDE CHAT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON MONDAY, JUNE 8, 2026 AT 8:40 A.M.

GERON TO PARTICIPATE IN THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

FOSTER CITY, CALIF., MAY 18, 2026 (GLOBE NEWSWIRE) -- GERON CORPORATION (NASDAQ: GERN), A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY REPORTED THAT, EFFECTIVE MAY 15, 2026, IT GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 333,750 SHARES OF COMMON STOCK TO FIVE NEWLY HIRED EMPLOYEES AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH GERON.

INVESTIGATOR-SPONSORED STUDY, CONDUCTED AT THE MOFFITT CANCER CENTER, DEMONSTRATES SAFETY AND EFFICACY CONSISTENT WITH THE PHASE 3 IMERGE TRIAL IN A BROADER PATIENT POPULATION

FIRST REAL-WORLD EVIDENCE STUDY OF RYTELO (IMETELSTAT) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) TO BE PRESENTED AT EHA 2026

ACHIEVED $51.8 MILLION IN RYTELO  (IMETELSTAT) NET PRODUCT REVENUE IN Q1 2026, AN INCREASE OF 8% COMPARED TO THE FOURTH QUARTER 2025 REITERATED 2026 RYTELO NET PRODUCT REVENUE AND TOTAL OPERATING EXPENSES EXPECTED TO BE IN THE RANGES OF $220 MILLION TO $240 MILLION, AND $230 MILLION TO $240 MILLION, RESPECTIVELY STRENGTHENED LEADERSHIP TEAM WITH APPOINTMENTS OF TIMOTHY WILLIAMS AS EXECUTIVE VICE PRESIDENT, CHIEF LEGAL OFFICER AND CORPORATE SECRETARY AND PATRICIA S. ANDREWS AND CONSTANTINE CHINOPOROS TO BOARD OF DIRECTORS ENDED Q1 2026WITH CASH, CASH EQUIVALENTS, RESTRICTEDCASHAND MARKETABLE SECURITIES OF$341 MILLION COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, MAY 6, 2026, AT 8:00 A.M.

Geron Corporation

GERN

Price

Financial Reports

No items found.

Press Releases

Geron Corporation

GERN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GERN